ELIS is a tactical, daily-reset way to bet against (or hedge) a pharma juggernaut—making timing, catalysts, and volatility decay more important than valuation alone.
Overview
Direxion Daily LLY Bear 1X Shares (ELIS) is an actively managed, non-diversified inverse ETF (launched March 25, 2025) designed to deliver -100% of Eli Lilly’s (LLY) *daily* price performance before fees and expenses. It uses derivatives (primarily swaps and options) rather than direct shorting, and it resets daily—meaning longer holding periods can materially diverge from a simple “short LLY” due to compounding effects and volatility decay. ELIS is positioned as a tactical instrument, reinforced by its relatively high expense ratio (~0.97%–0.99%) and small AUM (~$1.7M–$2.6M), which make it better suited to short-term hedging or event-driven speculation than strategic long-term positioning. The underlying reference company, Eli Lilly, is a global pharmaceutical leader whose current financial momentum is dominated by incretin-based therapies for diabetes and obesity. In Q4 2025, “Key Products” (including Mounjaro and Zepbound) grew ~91% YoY to ~$13.8B, with U.S. demand driving ~$12.9B of quarterly revenue amid higher volumes (despite lower realized prices). International expansion is accelerating as new markets open and ex-U.S. Mounjaro volume doubled in late 2025. ELIS rises when these revenue streams face meaningful headwinds (regulatory pricing, clinical setbacks, competitive erosion), but holding it against a structurally compounding growth story carries significant risk.